[German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm]
- PMID: 22930110
- DOI: 10.1007/s00393-012-1038-0
[German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm]
Abstract
Following the EULAR recommendations published in 2010 German guidelines for the medical treatment of rheumatoid arthritis were developed based on an update of the systematic literature search and expert consensus. Methotrexate is the standard treatment option at the time of diagnosis, preferably in combination with low dose glucocorticoids. Combined disease-modifying antirheumatic drugs (DMARD) therapy should be considered in patients not responding within 12 weeks. Treatment with biologicals should be initiated in patients with persistent high activity no later than 6 months after conventional treatment and in exceptional situations (e.g. early destruction or unfavorable prognosis) even earlier. If treatment with biologicals remains ineffective, changing to another biological is recommended after 3-6 months. In cases of long-standing remission a controlled reduction of medical treatment can be considered.
Similar articles
-
German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.Rheumatol Int. 2014 Jan;34(1):1-9. doi: 10.1007/s00296-013-2848-3. Epub 2013 Aug 14. Rheumatol Int. 2014. PMID: 23942828 Review.
-
The new 2012 German recommendations for treating rheumatoid arthritis : differences compared to the European standpoint.Z Rheumatol. 2013 Feb;72(1):6-9. doi: 10.1007/s00393-012-1093-6. Z Rheumatol. 2013. PMID: 23392597 Free PMC article.
-
Update of French society for rheumatology recommendations for managing rheumatoid arthritis.Joint Bone Spine. 2019 Mar;86(2):135-150. doi: 10.1016/j.jbspin.2018.10.002. Epub 2018 Oct 10. Joint Bone Spine. 2019. PMID: 30315988
-
Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis.Joint Bone Spine. 2007 Dec;74(6):627-37. doi: 10.1016/j.jbspin.2007.10.001. Epub 2007 Oct 29. Joint Bone Spine. 2007. PMID: 18037319
-
[How early would we really administer biologics?].Z Rheumatol. 2012 Dec;71(10):838-9. doi: 10.1007/s00393-012-1072-y. Z Rheumatol. 2012. PMID: 23202994 German.
Cited by
-
Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data.Rheumatol Int. 2018 Nov;38(11):2111-2120. doi: 10.1007/s00296-018-4161-7. Epub 2018 Oct 10. Rheumatol Int. 2018. PMID: 30306254 Free PMC article.
-
[B cell therapy of rheumatoid arthritis with rituximab. Practice-relevant aspects for the routine].Z Rheumatol. 2015 Apr;74(3):250-7. doi: 10.1007/s00393-014-1563-0. Z Rheumatol. 2015. PMID: 25854158 Review. German.
-
Etanercept in Axial Spondyloarthritis, Psoriatic Arthritis, and Plaque Psoriasis: Real-World Outcome Data from German Non-interventional Study ADEQUATE.Rheumatol Ther. 2024 Apr;11(2):331-348. doi: 10.1007/s40744-023-00633-2. Epub 2024 Feb 3. Rheumatol Ther. 2024. PMID: 38308727 Free PMC article.
-
German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.Rheumatol Int. 2014 Jan;34(1):1-9. doi: 10.1007/s00296-013-2848-3. Epub 2013 Aug 14. Rheumatol Int. 2014. PMID: 23942828 Review.
-
[Pharmacological treatment of rheumatoid arthritis and its comorbidities].Internist (Berl). 2018 Apr;59(4):341-351. doi: 10.1007/s00108-018-0397-2. Internist (Berl). 2018. PMID: 29508003 Review. German.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical